MEDP
Medpace Holdings, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$654.69
−1.33%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$672.72
From 52W high−5.48%
Volume25841.00
Market cap$18.31B
P/E (TTM)35.7x
P/S (TTM)6.5x
Div yield—
Key dataNov 4, 2026
Open
$672.72
From 52W high
−5.48%
Volume
25841.00
Market cap
$18.31B
ValuationView details →
P/E (Fwd)
34.0x
EV/EBITDA
27.6x
P/E (TTM)
35.7x
RSI (14)
59.9
MomentumView details →
1D Return
−1.33%
YTD Return
+19.65%
SummaryUpdated Sep 1, 2026
Medpace Holdings, Inc. (NASDAQ:MEDP) is a Cincinnati-based contract research organization (CRO) founded in 1992 that provides clinical trial services to pharmaceutical, biotechnology, and medical device companies. The company went public in August 2016 and has established itself as a specialized CRO focused primarily on serving biotech clients through the complete clinical development process from Phase I through Phase IV trials across various therapeutic areas.
Similar companies
Latest newsMore news →
Medpace Holdings, Inc. reported quarterly earnings of $4.84 per share, above the Zacks Investment Research, Inc. Consensus Estimate of $4.45 and compared with $3.86 per share a year earlier.14d agoMedpace Holdings, Inc. shares slipped late Wednesday.14d agoMedpace Holdings reported third-quarter 2026 revenue of $716.0 million, up 8.5% from $659.9 million a year earlier.14d ago